Q-omics provides the consensus-scored SH3GL3 profile across patient tissues and cancer cell-line models. SH3GL3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SH3GL3 is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, SH3GL3 RNA expression shows 21,359 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, LUAD, and GBM as cancer lineages where SH3GL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SH3GL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SH3GL3 survival associations across molecular data types. SH3GL3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SH3GL3 RNA expression–survival associations across cancer types. High SH3GL3 expression shows unfavorable associations in KIRC, COAD, MESO, BLCA, ACC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SH3GL3 RNA expression.
This table summarizes SH3GL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SH3GL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SH3GL3 shows lower tumor expression in LUAD, KIRC, LUSC, COAD, KICH and STAD. The LUAD box plot shows higher SH3GL3 RNA expression in normal versus tumor tissue (log2 FC = −2.643, t-test p < 0.001).
This table shows molecular features associated with SH3GL3 in patient tissues and cancer cell lines. In patient samples, SH3GL3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SH3GL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_NSCLC_LUAD.
